PubMed ID:
16606818
Public Release Type:
Journal
Publication Year: 2006
Affiliation: Division of Nephrology, University of Alabama at Birmingham, USA. dtb@uab.edu
DOI:
https://doi.org/10.1001/archinte.166.7.797
Authors:
Wang X,
Lash JP,
Appel LJ,
Agodoa LY,
Cheek D,
Contreras G,
Gassman J,
Miller ER,
Randall OS,
Thornley-Brown D,
Wright JT Jr
The African American Study of Kidney Disease and Hypertension was a multicenter trial of African Americans with hypertensive kidney disease randomized to an angiotensin-converting enzyme inhibitor (ramipril), a beta-blocker (metoprolol succinate), or a calcium channel blocker (amlodipine besylate). We compared the incidence of type 2 diabetes mellitus (DM) and the composite outcome of impaired fasting glucose or DM (IFG/DM) for the African American Study of Kidney Disease and Hypertension interventions.